Céline Louapre1, Elisabeth Maillart1, Caroline Papeix1, Sinead Zeidan1, Damien Biotti2, Zoé Lepine2, Abir Wahab3, Mickael Zedet4, Pierre Labauge5, Caroline Tilikete6, Julie Pique7, Ayman Tourbah8, Guillaume Mathey9,10, Dalia Dimitri Boulos11, Pierre Branger12, Laurent Daniel Kremer13, Romain Marignier7, Nicolas Collongues13, Jérôme De Seze13. 1. Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Institut du Cerveau, CIC Neuroscience, ICM, Hôpital de la Pitié Salpêtrière, Sorbonne Université, Paris, France. 2. Pole des Neurosciences, B4 Neurology Unit, Centre de ressources et de compétences Sclérose en plaques, CHU Purpan, Toulouse, France. 3. Service de Neurologie et CRC SEP, Groupe Hospitalier Henri Mondor, APHP, UPEC Université, Créteil, France. 4. Unité de neurologie inflammatoire, Département de Neurologie, Hôpital Roger Salengro, Chu de Lille, Lille, France. 5. Département de neurologie, CHU de Montpellier, Montpellier, France. 6. Equipe impact, Service de Neurocognition et Neuro-ophtalmologie, Groupe Hospitalier Est, Centre de Recherche en Neurosciences de Lyon, Hospices Civils de Lyon, Université de Lyon, Lyon, France. 7. Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), Service de neurologie, sclérose en plaques, Pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France. 8. Service de Neurologie, Hôpital Raymond Poincaré, UFR Simone Veil UVSQ, Université Paris Saclay, Garches, France. 9. Service de neurologie, Centre Régional Hospitalo-Universitaire de Nancy, Hôpital Central, Nancy, France. 10. Université de Lorraine, Vandoeuvre-lès-Nancy, France. 11. Service de neurologie, CHU Bicêtre, Le Kremlin Bicêtre, France. 12. Service de Neurologie, CHU de Caen Normandie, Caen, France. 13. Service de Neurologie and CIC INSERM 1434, CHU de Strasbourg, Strasbourg, France.
Abstract
BACKGROUND: Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown. METHODS: We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID-19 between 1 March 2020 and 30 June 2020. Main outcome was COVID-19 severity score assessed on a seven-point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death). RESULTS: Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24-year-old patient with positive aquaporine-4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti-CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0-4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0-6.5]). CONCLUSIONS: COVID-19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID-19; however, we recommend personal protective measures to reduce risk of SARS-CoV-2 infection in this immunocompromised population.
BACKGROUND: Outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown. METHODS: We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID-19 between 1 March 2020 and 30 June 2020. Main outcome was COVID-19 severity score assessed on a seven-point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death). RESULTS: Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24-year-old patient with positive aquaporine-4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti-CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0-4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0-6.5]). CONCLUSIONS: COVID-19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID-19; however, we recommend personal protective measures to reduce risk of SARS-CoV-2 infection in this immunocompromised population.
Authors: Vanja Jovicevic; Jovana Ivanovic; Marko Andabaka; Olivera Tamas; Nikola Veselinovic; Nikola Momcilovic; Sarlota Mesaros; Tatjana Pekmezovic; Jelena Drulovic Journal: Mult Scler Relat Disord Date: 2021-10-20 Impact factor: 4.339
Authors: Stefan Winkler; Judith H Aberle; Selma Tobudic; Barbara Kornek; Fritz Leutmezer; Paulus S Rommer; Maximilian Koblischke; Lisa Schneider; Helmuth Haslacher; Renate Thalhammer; Fritz Zimprich; Gudrun Zulehner; Gabriel Bsteh; Assunta Dal-Bianco; Walter Rinner; Karin Zebenholzer; Isabella Wimmer; Anja Steinmaurer; Marianne Graninger; Margareta Mayer; Kilian Roedl; Thomas Berger Journal: Ann Neurol Date: 2022-02-08 Impact factor: 11.274